IPOX® Associate Muehlbauer commented in Reuters on Doncasters’ planned U.S. IPO, as the aerospace parts maker targets a valuation of up to $4.43 billion and seeks to raise as much as $746.7 million. Muehlbauer noted that aerospace and defense sector momentum could support strong pricing, especially for companies showing demand through government contracts, long-term agreements and backlogs. He also cautioned that investors will focus on whether Doncasters’ capacity investments can translate into profits as it remains loss-making during expansion.

IPOX® CEO Josef Schuster was featured in Nikkei, commenting on SpaceX’s Nasdaq debut and its implications for future large IPOs. Schuster said the strong post-listing performance reflected robust demand and highlighted the depth of U.S. capital markets. The article also cited Jay Ritter, who cautioned that SpaceX’s high price-to-sales ratio and speculative growth areas could create downside risk. Schuster noted that news may drive shares short term, while fundamentals will become more important after earnings reports for investors and markets.

IPOX® Associate Lukas Muehlbauer was cited by Reuters on Kardigan’s planned U.S. IPO, which targets a valuation of up to $1.4 billion and aims to raise as much as $373.3 million. Muehlbauer noted a “clear uptick in biotech IPOs” and said healthcare IPO activity has already surpassed last year’s deal flow, signaling an open window for the sector. He also cautioned that investors remain selective, favoring companies with clinical progress and clearer paths to FDA approval.

IPOX® Associate Muehlbauer was interviewed for ZEIT ONLINE, the digital news platform of the German weekly newspaper DIE ZEIT, on the market impact of major planned IPOs and new share offerings. He discussed SpaceX’s expected $75 billion raise, possible listings from leading AI companies, and the challenge of absorbing significant new equity supply. He also noted that later insider sales may be the more important liquidity test for investors after the initial IPO.

IPOX® Associate Dr. Lukas Muehlbauer was quoted by Reuters on ERock’s NYSE debut after the gas generator maker’s shares opened below their IPO price, valuing the company at $5.49 billion. Muehlbauer said investors were pushing back on valuation amid execution risk, noting that ERock’s growth angle is tied to a substantial backlog from data center power demand, but the market wants proof that backlog can convert into revenue before assigning the company a more premium public-market valuation after its listing.